TRAIL C1595T Variant Critically Alters the Level of sTRAIL in Terms of Histopathological Parameters in Colorectal Cancer

Basit Öğe Kaydı
dc.authoridYILDIZ, Yemliha/0000-0002-1741-0503
dc.authoridYaylim, Ilhan/0000-0003-2615-0202
dc.contributor.authorHorozoglu, Cem
dc.contributor.authorYildiz, Asli
dc.contributor.authorSonmez, Dilara
dc.contributor.authorDemirkol, Seyda
dc.contributor.authorYildiz, Yemliha
dc.contributor.authorArikan, Soykan
dc.contributor.authorYaylim, Ilhan
dc.date.accessioned2024-05-19T14:40:15Z
dc.date.available2024-05-19T14:40:15Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractTRAIL, a member of the TNF family, is expressed in tumor and tumor surrounding tissue in many solid organ cancers. While the induction of tumor-specific apoptosis in correlation with cytokine stimulation may cause anti-tumoral effects, the pro-tumorigenic effects of its expression by tumor surrounding tissue members have been reported in the literature. In our study, it was aimed to evaluate the effect of the gene variant of TRAIL on soluble levels in patients with colorectal cancer (CRC) on the molecular pathological axis. TRAIL C1595 gene variant PCR-RFLP and sTRAIL levels were determined by ELISA in age and sex adjusted CRC and control groups. It was determined that CT carriage was high in patients without perineural invasion and sTRAIL levels were approximately 2.72 times lower than CC in patients with CT in this group (p < 0.05). Similarly, sTRAIL level was found to be high in patients with CC genotype in CRC without lymph node metastas. It was determined that CT carriage was high in patients without perineural invasion and sTRAIL levels were approximately 2.49 times lower than CC in patients with CT in this group.is (p < 0.05). We think that TRAIL C1595T in CRC can change sTRAIL levels in the clinicopathological axis in advanced stages such as metastasis and invasion, but both are not independent risk factors.en_US
dc.description.sponsorshipIstanbul University Scientific Research Projects Unit [TYO-2019-33675]en_US
dc.description.sponsorshipThis work was supported by the Istanbul University Scientific Research Projects Unit [Grant Number TYO-2019-33675].en_US
dc.identifier.doi10.1007/s12291-023-01146-z
dc.identifier.issn0970-1915
dc.identifier.issn0974-0422
dc.identifier.scopus2-s2.0-85167356348en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1007/s12291-023-01146-z
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4931
dc.identifier.wosWOS:001044828300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofIndian Journal of Clinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectColorectal Canceren_US
dc.subjectTrail C1595ten_US
dc.subjectStrailen_US
dc.titleTRAIL C1595T Variant Critically Alters the Level of sTRAIL in Terms of Histopathological Parameters in Colorectal Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu